Most Americans are wary of AI, but regular users show far higher trust, proving comfort grows with experience.
Data shows the first decline in obesity rates in US adults, but children and teens moved in the opposite direction.
Videos backed by thin evidence rack up views on YouTube, raising stakes for stricter creator guidelines.
New AI capabilities add clinician-vetted, empathetic guidance for women—the predominant segment of its user base.
Drugmakers’ price drops don’t affect all patients the same. Brands and marketers must decode cost complexities where patients already seek out weight loss advice, like on social media.
Two-thirds of clinicians stop engaging with content after clunky interactions.
The offering lets employers subsidize employees’ cash-pay price—sidestepping opaque PBM rebates and helping rein in rising pharmacy costs.
Rising legal and regulatory scrutiny of compounded weight loss drugs suggests branded pharma ties are the safer avenue for telehealth players to sell their copycat GLP-1s.
Its pharma ad lawsuit against J&J’s promotions lands amid rising enforcement and shrinking tolerance for bold claims.
Novo’s drug candidate CagriSema lagged Lilly’s Zepbound in weight loss trials, sending Novo shares down 15% and widening Lilly’s market lead.
Quicker, reliable AI notes help clinicians reclaim minutes they can spend on patients, even as AI accuracy concerns persist.
Tragic news moves consumers’ health choices, signaling to healthcare marketers that they need to pay attention to key cultural moments, not just paid celebrity endorsements.
Justices curb Trump’s tariffs, but a national security case could sustain pharma import taxes.
Single-study clinical trials (versus two) become the default, speeding up common drug approvals, while vaccines still face tougher scrutiny.
After an unusual review rejection, the FDA reverses course—a regulatory whiplash that could raise concerns about regulatory consistency.
The Eucalyptus deal deepens global reach as diversification beyond compounded GLP-1s in the US becomes urgent.
As AI tools steer more healthcare decisions, providers and insurers must target high-value use cases, carefully vet vendors, and lock in governance early.
Healthcare and pharma marketers should ramp up social listening and host expert Ask Me Anything sessions to drive engagement without feeling intrusive.
The FDA’s plans for broader access of medications could boost convenience, but also raise safety risks and drug costs.
Doctors watch less TV than the average US adult, but favor CTV and on-demand—which are prime time for targeted pharma messaging.